Esperion Therapeutics Inc (ESPR) 14.38 $ESPR
Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports First Quarter 2014 Financial Results
Business Wire - Mon May 12, 3:05PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provided ETC-1002 development program updates and financial results for the first quarter ended Mar. 31, 2014.
Hypercholesterolemia - Pipeline Review, H1 2014: 22 Company and 41 Drug Profiled
M2 - Wed May 07, 9:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sxbqm/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Alnylam Pharmaceuticals, Inc. - Amgen Astellas BioPharma K.K. - Bristol-Myers Squibb Company - Catabasis Pharmaceuticals, Inc. - Dybly AG - Eli Lilly and Company - Esperion Therapeutics, Inc. - FORMAC Pharmaceuticals N.V. - Immune Response BioPharma, Inc. - Johnson & Johnson - LondonPharma Ltd - Lumena Pharmaceuticals, Inc. - Madeira Therapeutics - Merck & Co., Inc. - NanoForm Therapeutics Ltd. - Pfizer Inc. - Planet Biotechnology Inc. - Regeneron Pharmaceuticals, Inc. - Relypsa, Inc. - Santaris Pharma A/S - Serometrix, LLC - Zhejiang Hisun Pharmaceutical Co., Ltd. Drug Profiles: - anacetrapib - alirocumab - evolocumab - bococizumab - ETC-1002 - Alpha Cyclodextrin - evolocumab - BMS-770767 - bococizumab - LY-3015014 - CAT-2003 - SPC-4955 - MGL-3196 - ALN-PCS02 - SPC-5001 - BMS-962476 - ralpancizumab - BMS-852927 - fenofibrate - simvastatin - fluvastatin sodium - pravastatin sodium - LUM-002 - PF-06678552 - HS-25 - ALN-PCS02 - RLY-106 - atorvastatin calcium - 1D05-Fab - IR-1002 For more information visit http://www.researchandmarkets.com/research/7s...lesterolem
Dyslipidemia - Pipeline Review, H1 2014: 43 Company and 69 Drug Profiles
M2 - Wed May 07, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2x75xp/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acasti Pharma Inc. - Alder Biopharmaceuticals Inc. - Amgen Inc. - Arisaph Pharmaceuticals, Inc. - Biocon Limited - Biospherics.net Incorporated - Cadila Pharmaceuticals Ltd. - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics SA - Chong Kun Dang Pharmaceutical Corp. - Daiichi Sankyo Company, Limited - Dezima Pharma B.V. - Dr. Reddy's Laboratories Limited - Eli Lilly and Company - Esperion Therapeutics, Inc. - Essentialis, Inc. - Euroscreen S.A. - GW Pharmaceuticals plc - Genfit SA - GlaxoSmithKline plc - Glenmark Pharmaceuticals Ltd. - High Point Pharmaceuticals, LLC - Jenrin Discovery, Inc. - Johnson & Johnson - Kadmon Pharmaceuticals, LLC - Kareus Therapeutics, SA - Kissei Pharmaceutical Co., Ltd. - Kotobuki Pharmaceutical Co., Ltd. - Kowa Company, Ltd. Drug Profiles: - anacetrapib - K-877 - Nicotinic Acid - (rosuvastatin calcium ezetimibe) - Centatin - DEZ-001 - GFT-505 - DRL-17822 - K-877 - ZYH-7 - 1-Methylnicotinamide - ETC-1002 - diazoxide CR - evacetrapib - (niacin aspirin) - GWP-42003 - KD-026 - S-556971 - GWP-42004 - MGL-3196 - ARI-3037-MO - ZYT-1 - HPP-593 - NC-2400 - TAP-311 - S-556971 - DS-1442 - K-312 - SPX-8522876 For more information visit http://www.researchandmarkets.com/research/2x...slipidemia
Esperion Therapeutics to Present at Bank of America Merrill Lynch Healthcare Conference
Business Wire - Tue May 06, 3:30PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced the Company will present at the 2014 Bank of America Merrill Lynch Healthcare Conference in Las Vegas, Nev. Tim M. Mayleben, president and chief executive officer, will provide updates on the company on Tuesday, May 13 at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time.
Esperion Therapeutics to Provide First Quarter 2014 Financial Results
Business Wire - Mon May 05, 7:05AM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced that it will host a conference call and webcast to report first quarter 2014 operational and financial results. The webcast will take place on Monday, May 12, 2014 at 4:30 p.m. Eastern Time.
Esperion Therapeutics to Deliver Three Scientific Poster Presentations at the 2014 Annual Scientific Sessions of the National Lipid Association
Business Wire - Thu May 01, 3:30PM CDT
Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the company will deliver three posters featuring ETC-1002 Phase 2 clinical results at the 2014 Annual Scientific Sessions of the National Lipid Association in Orlando, Fla. The posters provide additional information from previously-presented Phase 2 studies of ETC-1002, and new analyses regarding blood pressure lowering in patients with both hypercholesterolemia and mildly elevated blood pressure.
Esperion Therapeutics to Present at BioCentury Future Leaders in the Biotech Industry Conference
Business Wire - Mon Mar 24, 7:08AM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that Tim M. Mayleben, Esperion's president and chief executive officer, will present at the 21st Annual BioCentury Future Leaders in the Biotech Industry conference in New York City. The presentation and webcast will take place on Friday, March 28, 2014 at 2:30 p.m. Eastern Time.
Esperion Therapeutics (ESPR) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:21AM CDT
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
Esperion Therapeutics Provides ETC-1002 Program Update; Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Wed Mar 05, 3:05PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provided ETC-1002 development program updates and reported its financial results for the fourth quarter and full year ended Dec. 31, 2013.
Esperion Therapeutics to Provide ETC-1002 Program Update; Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Wed Feb 26, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that it will host a conference call and webcast to provide program development updates and discuss financial results for the fourth quarter and full year ended Dec. 31, 2013. The webcast will take place following NASDAQ Market close on Wednesday, March 5, 2014 at 4:30 p.m. Eastern Time.
Esperion Therapeutics, Inc.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:58PM CST
Pure Multi-Family REIT LP ("Pure Multi"
(TSXV: RUF.U) announced today that the Board of Directors of Pure Multi-Family REIT (GP) Inc., the governing general partner of Pure Multi, has approved a cash distribution of US$0.03 per unit for the month of February 2013 (equivalent to US$0.36 per unit on an annualized basis). The distribution will be paid on March 15, 2013 to unitholders of record at the close of business on February 28, 2013.
Esperion Therapeutics Names Mark E. McGovern, M.D., FACC, FACP, Director
Business Wire - Thu Feb 13, 7:05AM CST
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Mark E. McGovern, M.D., FACC, FACP, as a Director. Dr. McGovern will serve as a Class I director with a term of office expiring at the 2014 annual meeting of stockholders.
Innovative Food Holdings, Inc. Presents at MicroCapClub Invitational
Marketwire - Tue Feb 04, 7:45AM CST
Innovative Food Holdings, Inc. (OTCQB: IVFH) announced today it has been selected to present at the 2nd annual MicroCapClub Invitational.
Esperion Therapeutics Inc elects Dr Antonio M. Gotto Jr as director
M2 - Tue Jan 14, 6:11AM CST
Biopharmaceutical company Esperion Therapeutics Inc (NasdaqGM:ESPR) revealed on Monday the addition of Dr. Antonio M. Gotto Jr, MD, DPhil as its director.
Esperion Therapeutics Announces the Appointment of Antonio M. Gotto Jr., M.D., DPhil, as Director
Business Wire - Mon Jan 13, 7:00AM CST
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Antonio M. Gotto Jr., M.D., DPhil as a Director of the Company. Dr. Gotto will serve as a Class II director with a term of office expiring at our 2015 annual meeting of stockholders.
United Kingdom Quarterly Beverage Tracker Report Q22013
PR Newswire - Tue Jan 07, 8:57AM CST
Reportbuyer.com just published a new market research report:
Esperion Therapeutics Added to the NASDAQ Biotechnology Index
Business Wire - Mon Dec 23, 3:05PM CST
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that the company has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on December 23, 2013. The Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market(R) (NASDAQ(R)) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). This is the most recent index to which the company has been added in 2013. The company is also included in the Russell Global, 3000, 2000, and Microcap indices, and the MSCI Global Micro Cap indices.
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 16, 7:05AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 23, 2013.
Hyperglycemia - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/tlz435/hyperglycemia) has announced the addition of the "Hyperglycemia - Pipeline Review, H2 2013" report to their offering. 'Hyperglycemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hyperglycemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperglycemia. The analysis is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Hyperglycemia. - A review of the Hyperglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hyperglycemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hyperglycemia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Hyperglycemia Overview Therapeutics Development Companies Involved in Hyperglycemia Therapeutics Development Drug Profiles - RLY-106 - Oligotide - Insumera - Sodium Glucose Co-Transporter 1 Inhibitors - KR-62980 - ZLN-005 - ESP-41091 Featured News & Press Releases Appendix Companies Mentioned - Esperion Therapeutics, Inc. - GENTIUM S.p.A. - Kissei Pharmaceutical Co., Ltd. - PhaseBio Pharmaceuticals, Inc. - Relypsa, Inc. For more information visit http://www.researchandmarkets.com/research/tl...erglycemia
Esperion Therapeutics Presents Full Results of Phase 2 Clinical Study Demonstrating that ETC-1002 Lowered LDL-C by an Average of 32 Percent and Was Well Tolerated in Patients with Hypercholesterolemia and History of Statin Intolerance
Business Wire - Mon Nov 18, 7:00AM CST
Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced full results of a Phase 2 clinical study of its lead product candidate ETC-1002 in patients with hypercholesterolemia and a history of statin intolerance. The study, ETC-1002-006, met its primary endpoint, demonstrating that ETC-1002 significantly lowered LDL-C compared to placebo by an average of 32 percent and was well tolerated. The data were presented today in an oral presentation at the 2013 Scientific Sessions of the American Heart Association in Dallas by principal investigator Paul D. Thompson, M.D. Esperion previously announced positive topline results from this study in June 2013.
Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports First Quarter 2014 Financial Results
Business Wire - Mon May 12, 3:05PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provided ETC-1002 development program updates and financial results for the first quarter ended Mar. 31, 2014.
Hypercholesterolemia - Pipeline Review, H1 2014: 22 Company and 41 Drug Profiled
M2 - Wed May 07, 9:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sxbqm/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Alnylam Pharmaceuticals, Inc. - Amgen Astellas BioPharma K.K. - Bristol-Myers Squibb Company - Catabasis Pharmaceuticals, Inc. - Dybly AG - Eli Lilly and Company - Esperion Therapeutics, Inc. - FORMAC Pharmaceuticals N.V. - Immune Response BioPharma, Inc. - Johnson & Johnson - LondonPharma Ltd - Lumena Pharmaceuticals, Inc. - Madeira Therapeutics - Merck & Co., Inc. - NanoForm Therapeutics Ltd. - Pfizer Inc. - Planet Biotechnology Inc. - Regeneron Pharmaceuticals, Inc. - Relypsa, Inc. - Santaris Pharma A/S - Serometrix, LLC - Zhejiang Hisun Pharmaceutical Co., Ltd. Drug Profiles: - anacetrapib - alirocumab - evolocumab - bococizumab - ETC-1002 - Alpha Cyclodextrin - evolocumab - BMS-770767 - bococizumab - LY-3015014 - CAT-2003 - SPC-4955 - MGL-3196 - ALN-PCS02 - SPC-5001 - BMS-962476 - ralpancizumab - BMS-852927 - fenofibrate - simvastatin - fluvastatin sodium - pravastatin sodium - LUM-002 - PF-06678552 - HS-25 - ALN-PCS02 - RLY-106 - atorvastatin calcium - 1D05-Fab - IR-1002 For more information visit http://www.researchandmarkets.com/research/7s...lesterolem
Dyslipidemia - Pipeline Review, H1 2014: 43 Company and 69 Drug Profiles
M2 - Wed May 07, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2x75xp/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acasti Pharma Inc. - Alder Biopharmaceuticals Inc. - Amgen Inc. - Arisaph Pharmaceuticals, Inc. - Biocon Limited - Biospherics.net Incorporated - Cadila Pharmaceuticals Ltd. - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics SA - Chong Kun Dang Pharmaceutical Corp. - Daiichi Sankyo Company, Limited - Dezima Pharma B.V. - Dr. Reddy's Laboratories Limited - Eli Lilly and Company - Esperion Therapeutics, Inc. - Essentialis, Inc. - Euroscreen S.A. - GW Pharmaceuticals plc - Genfit SA - GlaxoSmithKline plc - Glenmark Pharmaceuticals Ltd. - High Point Pharmaceuticals, LLC - Jenrin Discovery, Inc. - Johnson & Johnson - Kadmon Pharmaceuticals, LLC - Kareus Therapeutics, SA - Kissei Pharmaceutical Co., Ltd. - Kotobuki Pharmaceutical Co., Ltd. - Kowa Company, Ltd. Drug Profiles: - anacetrapib - K-877 - Nicotinic Acid - (rosuvastatin calcium ezetimibe) - Centatin - DEZ-001 - GFT-505 - DRL-17822 - K-877 - ZYH-7 - 1-Methylnicotinamide - ETC-1002 - diazoxide CR - evacetrapib - (niacin aspirin) - GWP-42003 - KD-026 - S-556971 - GWP-42004 - MGL-3196 - ARI-3037-MO - ZYT-1 - HPP-593 - NC-2400 - TAP-311 - S-556971 - DS-1442 - K-312 - SPX-8522876 For more information visit http://www.researchandmarkets.com/research/2x...slipidemia
Esperion Therapeutics to Present at Bank of America Merrill Lynch Healthcare Conference
Business Wire - Tue May 06, 3:30PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced the Company will present at the 2014 Bank of America Merrill Lynch Healthcare Conference in Las Vegas, Nev. Tim M. Mayleben, president and chief executive officer, will provide updates on the company on Tuesday, May 13 at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time.
Esperion Therapeutics to Provide First Quarter 2014 Financial Results
Business Wire - Mon May 05, 7:05AM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced that it will host a conference call and webcast to report first quarter 2014 operational and financial results. The webcast will take place on Monday, May 12, 2014 at 4:30 p.m. Eastern Time.
Esperion Therapeutics to Deliver Three Scientific Poster Presentations at the 2014 Annual Scientific Sessions of the National Lipid Association
Business Wire - Thu May 01, 3:30PM CDT
Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the company will deliver three posters featuring ETC-1002 Phase 2 clinical results at the 2014 Annual Scientific Sessions of the National Lipid Association in Orlando, Fla. The posters provide additional information from previously-presented Phase 2 studies of ETC-1002, and new analyses regarding blood pressure lowering in patients with both hypercholesterolemia and mildly elevated blood pressure.
Esperion Therapeutics to Present at BioCentury Future Leaders in the Biotech Industry Conference
Business Wire - Mon Mar 24, 7:08AM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that Tim M. Mayleben, Esperion's president and chief executive officer, will present at the 21st Annual BioCentury Future Leaders in the Biotech Industry conference in New York City. The presentation and webcast will take place on Friday, March 28, 2014 at 2:30 p.m. Eastern Time.
Esperion Therapeutics (ESPR) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:21AM CDT
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
Esperion Therapeutics Provides ETC-1002 Program Update; Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Wed Mar 05, 3:05PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provided ETC-1002 development program updates and reported its financial results for the fourth quarter and full year ended Dec. 31, 2013.
Esperion Therapeutics to Provide ETC-1002 Program Update; Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Wed Feb 26, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that it will host a conference call and webcast to provide program development updates and discuss financial results for the fourth quarter and full year ended Dec. 31, 2013. The webcast will take place following NASDAQ Market close on Wednesday, March 5, 2014 at 4:30 p.m. Eastern Time.
Esperion Therapeutics, Inc.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:58PM CST
Pure Multi-Family REIT LP ("Pure Multi"
(TSXV: RUF.U) announced today that the Board of Directors of Pure Multi-Family REIT (GP) Inc., the governing general partner of Pure Multi, has approved a cash distribution of US$0.03 per unit for the month of February 2013 (equivalent to US$0.36 per unit on an annualized basis). The distribution will be paid on March 15, 2013 to unitholders of record at the close of business on February 28, 2013. Esperion Therapeutics Names Mark E. McGovern, M.D., FACC, FACP, Director
Business Wire - Thu Feb 13, 7:05AM CST
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Mark E. McGovern, M.D., FACC, FACP, as a Director. Dr. McGovern will serve as a Class I director with a term of office expiring at the 2014 annual meeting of stockholders.
Innovative Food Holdings, Inc. Presents at MicroCapClub Invitational
Marketwire - Tue Feb 04, 7:45AM CST
Innovative Food Holdings, Inc. (OTCQB: IVFH) announced today it has been selected to present at the 2nd annual MicroCapClub Invitational.
Esperion Therapeutics Inc elects Dr Antonio M. Gotto Jr as director
M2 - Tue Jan 14, 6:11AM CST
Biopharmaceutical company Esperion Therapeutics Inc (NasdaqGM:ESPR) revealed on Monday the addition of Dr. Antonio M. Gotto Jr, MD, DPhil as its director.
Esperion Therapeutics Announces the Appointment of Antonio M. Gotto Jr., M.D., DPhil, as Director
Business Wire - Mon Jan 13, 7:00AM CST
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Antonio M. Gotto Jr., M.D., DPhil as a Director of the Company. Dr. Gotto will serve as a Class II director with a term of office expiring at our 2015 annual meeting of stockholders.
United Kingdom Quarterly Beverage Tracker Report Q22013
PR Newswire - Tue Jan 07, 8:57AM CST
Reportbuyer.com just published a new market research report:
Esperion Therapeutics Added to the NASDAQ Biotechnology Index
Business Wire - Mon Dec 23, 3:05PM CST
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that the company has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on December 23, 2013. The Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market(R) (NASDAQ(R)) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). This is the most recent index to which the company has been added in 2013. The company is also included in the Russell Global, 3000, 2000, and Microcap indices, and the MSCI Global Micro Cap indices.
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 16, 7:05AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 23, 2013.
Hyperglycemia - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/tlz435/hyperglycemia) has announced the addition of the "Hyperglycemia - Pipeline Review, H2 2013" report to their offering. 'Hyperglycemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hyperglycemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperglycemia. The analysis is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Hyperglycemia. - A review of the Hyperglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hyperglycemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hyperglycemia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Hyperglycemia Overview Therapeutics Development Companies Involved in Hyperglycemia Therapeutics Development Drug Profiles - RLY-106 - Oligotide - Insumera - Sodium Glucose Co-Transporter 1 Inhibitors - KR-62980 - ZLN-005 - ESP-41091 Featured News & Press Releases Appendix Companies Mentioned - Esperion Therapeutics, Inc. - GENTIUM S.p.A. - Kissei Pharmaceutical Co., Ltd. - PhaseBio Pharmaceuticals, Inc. - Relypsa, Inc. For more information visit http://www.researchandmarkets.com/research/tl...erglycemia
Esperion Therapeutics Presents Full Results of Phase 2 Clinical Study Demonstrating that ETC-1002 Lowered LDL-C by an Average of 32 Percent and Was Well Tolerated in Patients with Hypercholesterolemia and History of Statin Intolerance
Business Wire - Mon Nov 18, 7:00AM CST
Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced full results of a Phase 2 clinical study of its lead product candidate ETC-1002 in patients with hypercholesterolemia and a history of statin intolerance. The study, ETC-1002-006, met its primary endpoint, demonstrating that ETC-1002 significantly lowered LDL-C compared to placebo by an average of 32 percent and was well tolerated. The data were presented today in an oral presentation at the 2013 Scientific Sessions of the American Heart Association in Dallas by principal investigator Paul D. Thompson, M.D. Esperion previously announced positive topline results from this study in June 2013.
